Swedish biotech chooses Recipharm for sepsis drug manufacturing


Recipharm has signed a deal with Aptahem to develop an injectable formulation for an upcoming Phase 1 study

Image as seen on company website

Image as seen on company website

International CDMO Recipharm has partnered with biotechnology company Aptahem for the formulation of Apta-1 drug candidate. The aptamer-based drug candidate is intended to treat life-threatening condition sepsis, a potentially fatal condition which involves a general inflammatory response, known as systemic inflammatory response syndrome (SIRS), caused by an infection.

Recipharm will develop an injectable formulation for the upcoming Phase 1 study.

Anders Högdin, Senior Sales Director at Recipharm, said: “Recipharm has extensive experience in developing drugs for clinical trials, as well as in commercial manufacturing and we believe that our team’s expertise will be a very valuable asset during this new collaboration.”

The partnership follows the positive results of Apta-1’s exploratory sepsis study with non-human primates (NHP) which provided a greater understanding of the anticoagulant, anti-inflammatory and immunomodulatory effects of the candidate and continued to support its multifunctional potential within its therapeutic area.

Sign up for your free email newsletter

Mikael Lindstam, CEO of Aptahem, said: “Choosing a partner to help us progress our drug candidate is a significant milestone. We are now moving at full speed ahead in the development process of Apta-1 and with this cooperation now established I am convinced that we will be able to accelerate further.”